NCT01836146View on ClinicalTrials.gov

International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension

NACompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 30, 2013

Primary Completion Date

March 31, 2014

Study Completion Date

September 30, 2015

Conditions
HypertensionRenal Denervation
Interventions
DEVICE

EnligHTN™ Renal Artery Ablation Catheter

Trial Locations (6)

1023

Auckland City Hospital, Auckland

9016

Dunedin Hospital, Dunedin

Unknown

St Andrews Hospital, Adelaide

St. Vincent's Hospital Melbourne, Fizroy

Monash Heart/Southern Health, Melbourne

Royal Melbourne Hospital, Melbourne

Sponsors
All Listed Sponsors
lead

Abbott Medical Devices

INDUSTRY

NCT01836146 - International First-in-Human Study of the EnligHTN Generation 2 System in Patients With Drug-resistant Uncontrolled Hypertension | Biotech Hunter | Biotech Hunter